Get Expert Advice for controlling your Severe Allergies

Hydroxyzine Pamoate

Pronunciation

Dosage Form: capsule

HydrOXYzinePamoate Capsules USP

Hydroxyzine Pamoate Description

Hydroxyzine Pamoate is a light yellow, practically odorless powder practically insoluble in water and methanol and freely soluble in dimethylformamide. It is chemically designated as (±)-2-[2-[4-(p-Chloro-α-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol 4,4’-methylenebis[3-hydroxy-2-naphthoate] (1:1) [10246-75-0] and can be structurally represented as follows:

Slideshow: 2014 Update - First Time Brand-to-Generic Switches

C21H27CIN2O2•C23H16O6

M.W. 763.27

Each capsule, for oral administration, contains Hydroxyzine Pamoate equivalent to hydroxyzine hydrochloride 25 mg or 50 mg.

In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, sodium starch glycolate (potato), and sodium lauryl sulfate.

The capsule shell contains the following ingredients: D&C Yellow #10, FD&C Green #3, FD&C Yellow #6, gelatin, and titanium dioxide.

The edible imprinting ink contains the following ingredients: black iron oxide, D&C Yellow #10, FD&C Blue #1, FD&C Blue #2, FD&C Red #40, and shellac glaze.

Hydroxyzine Pamoate - Clinical Pharmacology

Hydroxyzine Pamoate is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines.

Hydroxyzine Pamoate is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally. Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically.

An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.

Hydroxyzine is rapidly absorbed from the gastrointestinal tract and Hydroxyzine Pamoate clinical effects are usually noted within 15 to 30 minutes after oral administration.

INDICATIONS

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.

Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus.

As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (Demerol®) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.

The effectiveness of hydroxyzine as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.

Contraindications

Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.

Hydroxyzine Pamoate is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

Warnings

Nursing Mothers

It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

Precautions

THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine, their dosage should be reduced.

Since drowsiness may occur with use of the drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking Hydroxyzine Pamoate capsules. Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased.

Geriatric Use

A determination has not been made whether controlled clinical studies of Hydroxyzine Pamoate capsules included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.

The extent of renal excretion of Hydroxyzine Pamoate capsules has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.

Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of Hydroxyzine Pamoate capsules and observed closely.

Adverse Reactions

Side effects reported with the administration of Hydroxyzine Pamoate are usually mild and transitory in nature.

Skin and Appendages

Oral hydroxyzine hydrochloride is associated with fixed drug eruptions in post-marketing reports.

Anticholinergic

Dry mouth.

Central Nervous System

Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity, including rare instances of tremor and convulsions, has been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.

In post-marketing experience, the following additional undesirable effects have been reported:

Body as a Whole: allergic reaction

Nervous System: headache

Psychiatric: hallucination

Skin and Appendages: pruritus, rash, urticaria

Overdosage

The most common manifestation of overdosage of Hydroxyzine Pamoate is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and vasopressors (do not use epinephrine as hydroxyzine counteracts its pressor action.) Caffeine and Sodium Benzoate Injection, USP, may be used to counteract central nervous system depressant effects.

There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.

Hydroxyzine Pamoate Dosage and Administration

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50 mg to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50 mg to 100 mg daily in divided doses.

For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50 mg to 100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50 mg to 100 mg in adults, and 0.6 mg/kg in children. When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.

As with all medications, the dosage should be adjusted according to the patient’s response to therapy.

How is Hydroxyzine Pamoate Supplied

Hydroxyzine Pamoate Capsules USP, for oral administration, are available as:

25 mg: (equivalent to 25 mg hydroxyzine hydrochloride) are light green/dark green capsules imprinted “E 613” and supplied as:

NDC 0185-0674-01 bottles of 100

NDC 0185-0674-05 bottles of 500

NDC 0185-0674-10 bottles of 1000

50 mg: (equivalent to 50 mg hydroxyzine hydrochloride) are dark green/white capsules imprinted “E 615” and supplied as:

NDC 0185-0615-01 bottles of 100

NDC 0185-0615-05 bottles of 500

NDC 0185-0615-10 bottles of 1000

Storage

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Protect from moisture.

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

25 mg

Manufactured by

Sandoz Inc.

Princeton, NJ 08540

46114010

Rev. 07/14

50 mg

Manufactured for

Sandoz Inc.

Princeton, NJ 08540

Manufactured by

Epic Pharma, LLC

Laurelton, NY 11413

OS7127

Rev. 07/14

MF0674REV07/14

MG# 16920

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

NDC 0185-0613-01

HydrOXYzinePamoate Capsules USP

25 mg*

Contains FD&C Yellow No. 6 as a color additive.

Rx only

100 Capsules

Sandoz

Package/Label Display Panel

NDC 0185-0674-01 Capsule Size Change

HydrOXYzinePamoate Capsules USP

25 mg*

Rx only

100 Capsules

Sandoz

Package/Label Display Panel

NDC 0185-0615-01

HydrOXYzinePamoate Capsules USP

50 mg*

Rx only

100 Capsules

Sandoz

Hydroxyzine Pamoate 
Hydroxyzine Pamoate capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0185-0674
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Hydroxyzine Pamoate (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 25 mg
Inactive Ingredients
Ingredient Name Strength
SILICON DIOXIDE  
D&C YELLOW NO. 10  
FD&C GREEN NO. 3  
FD&C YELLOW NO. 6  
GELATIN  
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
SODIUM LAURYL SULFATE  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
TITANIUM DIOXIDE  
HYDROXYPROPYL CELLULOSE (TYPE H)  
FD&C BLUE NO. 1  
FD&C BLUE NO. 2  
FD&C RED NO. 40  
SHELLAC  
FERROSOFERRIC OXIDE  
Product Characteristics
Color GREEN (light green/dark green) Score no score
Shape CAPSULE Size 16mm
Flavor Imprint Code E613
Contains         
Packaging
# Item Code Package Description
1 NDC:0185-0674-10 1000 CAPSULE in 1 BOTTLE
2 NDC:0185-0674-05 500 CAPSULE in 1 BOTTLE
3 NDC:0185-0674-01 100 CAPSULE in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA087479 06/27/2014
Hydroxyzine Pamoate 
Hydroxyzine Pamoate capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0185-0613
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Hydroxyzine Pamoate (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 25 mg
Inactive Ingredients
Ingredient Name Strength
SILICON DIOXIDE  
D&C YELLOW NO. 10  
FD&C GREEN NO. 3  
FD&C YELLOW NO. 6  
GELATIN  
HYDROXYPROPYL CELLULOSE (TYPE H)  
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
SODIUM LAURYL SULFATE  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
TITANIUM DIOXIDE  
FD&C BLUE NO. 1  
FD&C BLUE NO. 2  
FD&C RED NO. 40  
SHELLAC  
FERROSOFERRIC OXIDE  
Product Characteristics
Color GREEN (light green/dark green) Score no score
Shape CAPSULE Size 19mm
Flavor Imprint Code E613
Contains         
Packaging
# Item Code Package Description
1 NDC:0185-0613-10 1000 CAPSULE in 1 BOTTLE
2 NDC:0185-0613-05 500 CAPSULE in 1 BOTTLE
3 NDC:0185-0613-01 100 CAPSULE in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA087479 12/14/1981 04/10/2019
Hydroxyzine Pamoate 
Hydroxyzine Pamoate capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0185-0615
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Hydroxyzine Pamoate (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 50 mg
Inactive Ingredients
Ingredient Name Strength
SILICON DIOXIDE  
D&C YELLOW NO. 10  
FD&C GREEN NO. 3  
FD&C YELLOW NO. 6  
GELATIN  
HYDROXYPROPYL CELLULOSE (TYPE H)  
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
SODIUM LAURYL SULFATE  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
TITANIUM DIOXIDE  
FD&C BLUE NO. 1  
FD&C BLUE NO. 2  
FD&C RED NO. 40  
SHELLAC  
FERROSOFERRIC OXIDE  
Product Characteristics
Color GREEN (white) Score no score
Shape CAPSULE Size 19mm
Flavor Imprint Code E615
Contains         
Packaging
# Item Code Package Description
1 NDC:0185-0615-10 1000 CAPSULE in 1 BOTTLE
2 NDC:0185-0615-05 500 CAPSULE in 1 BOTTLE
3 NDC:0185-0615-01 100 CAPSULE in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA086183 12/14/1981
Labeler - Eon Labs, Inc. (012656273)
Revised: 08/2014
 
Eon Labs, Inc.
Hide
(web5)